Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual H.C. Wainwright Global Investor Conference
NEW YORK, Sept. 10, 2020 /PRNewswire/ --Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its Chairman and Chief Executive Officer Sandesh Seth will be presenting at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14th at 2:00 PM EST.
NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its Chairman and Chief Executive Officer Sandesh Seth will be presenting at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14th at 2:00 PM EST.
Presentation details are as follows:
|
Event: |
H.C. Wainwright 22nd Annual Global Investment Conference |
|
Date: |
Monday, September 14TH |
|
Time: |
2:00 PM EST |
The presentation will be accessible on the investor relations section of Actinium Pharmaceuticals website at www.actiniumpharma.com
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for our ARCs is targeted conditioning, which is intended to selectively kill patient's cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, CAR-T and other cell therapies or gene therapy to enable engraftment of these transplanted cells with minimal toxicities. With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Our lead product candidate, Iomab-B is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SIERRA trial is over fifty percent enrolled and promising single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings. Beyond Iomab-B, we are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform. This is where our intellectual property portfolio of over 120 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster our pipeline for strategic purposes. Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc.
Investor Contact:
Clayton Robertson
Actinium Pharmaceuticals, Inc.
[email protected]
Hans Vitzthum
LifeSci Advisors, LLC
[email protected]
P: (617) 535-7743
View original content to download multimedia:http://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-to-present-at-the-22nd-annual-hc-wainwright-global-investor-conference-301127149.html
SOURCE Actinium Pharmaceuticals, Inc.
